Evidence map›Paper›PMID 42013603›Full record

ReviewCurrent opinion in microbiology2026

Manipulation of nonclassical ubiquitin signaling by pathogenic bacteria.

Jasleen Kaur Sidhu, Tomoko Kubori, Jonathan N Pruneda

Abstract readReview
In one paragraph

Review in Current opinion in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jasleen Kaur SidhuDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA.
Tomoko KuboriDepartment of Microbiology, Graduate School of Medicine, Gifu University, Gifu, Gifu 501-1194, Japan. Electronic address: kubori.tomoko.j0@f.gifu-u.ac.jp.
Jonathan N PrunedaDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: pruneda@ohsu.edu.

Funding

Program in Biomedical SciencesT32GM142619 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2021 to 2026
$3.2M
Exploiting bacterial effector proteins to study human ubiquitin signalingR35GM142486 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jonathan N Pruneda · 2021 to 2026
$2.6M
Bacterial manipulation of atypical ubiquitin signalingR01AI184933 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jonathan N Pruneda · 2025 to 2026
$1.3M
NIAID NIH HHS R01 AI184933NIGMS NIH HHS R35 GM142486NIGMS NIH HHS T32 GM142619
6 · The paper itself

Abstract

Manipulation of the host ubiquitin signaling system is emerging as a common and critical mechanism of virulence among pathogenic bacteria. In some cases, such as the intracellular pathogens Legionella pneumophila and Shigella flexneri, ubiquitin regulation is the focus of a significant proportion of the bacterial repertoire of secreted effectors (10% and 30%, respectively). While many of these bacterial effectors hijack classical aspects of the ubiquitin system, such as proteasomal degradation and immune signaling, others target nonclassical ubiquitin signals that are less well understood. These include so-called atypical polyubiquitin chain types, such as Lys6-linked chains, for which specific regulators and functions within human biology have remained elusive. Recent studies have also identified bacterial manipulation of so-called noncanonical ubiquitination, including modification of non-lysine as well as non-proteinaceous targets. Lastly, in select cases such as L. pneumophila, bacteria can impose an entirely orthogonal form of ubiquitin signaling that looks and behaves nothing like the eukaryotic system. Herein, we will review the most recent discoveries in bacterial manipulation of nonclassical ubiquitin signaling.

Indexed as

BacteriaHost-Pathogen InteractionsLegionella pneumophilaSignal TransductionUbiquitinAnimalsBacterial ProteinsHumansUbiquitinationBacterial ProteinsUbiquitin

Identifiers

PMID42013603
PMCPMC13143401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.